BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 35965418)

  • 1. Predictive Immune Markers for Disease Progression in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance.
    İşgör İŞ; Toptaş T; Türkoz HK
    Turk J Haematol; 2022 Dec; 39(4):245-253. PubMed ID: 35965418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of serum levels of Dickkopf-1 (DKK-1) in monoclonal gammopathy of undetermined significance and multiple myeloma].
    Ščudla V; Petrová P; Pika T; Lochman P; Minařík J; Bačovský J; Srovnalík K
    Cas Lek Cesk; 2015; 154(4):181-8. PubMed ID: 26357861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
    Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
    Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance : A Cohort Study Nested in a Clinical Trial.
    Eythorsson E; Rognvaldsson S; Thorsteinsdottir S; Einarsson Long T; Reed ER; Sigurdardottir GA; Vidarsson B; Onundarson PT; Agnarsson BA; Sigurdardottir M; Olafsson I; Thorsteinsdottir I; Sveinsdottir SV; Sigurdsson F; Thordardottir AR; Palsson R; Indridason OS; Jonsson A; Gislason GK; Olafsson A; Sigurdsson J; Steingrimsdottir H; Hultcrantz M; Durie BGM; Harding S; Landgren O; Aspelund T; Love TJ; Kristinsson SY
    Ann Intern Med; 2024 Apr; 177(4):449-457. PubMed ID: 38560901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
    Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Monoclonal gammopathy of undetermined significance and evolution to myeloma: Experience in 153 patients].
    López Gómez JM; Sacristán Enciso B; Fernández-Cavada Pollo MJ; Bueno García V; Gómez Vera S
    Semergen; 2021 Oct; 47(7):441-447. PubMed ID: 34479794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of microRNA-221/222 in patients with monoclonal gammopathy of undetermined significance and multiple myeloma].
    Yang S; Wang W; Jin H; Zhong Y; Xie X
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 May; 45(4):371-378. PubMed ID: 27868410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYC protein expression is detected in plasma cell myeloma but not in monoclonal gammopathy of undetermined significance (MGUS).
    Xiao R; Cerny J; Devitt K; Dresser K; Nath R; Ramanathan M; Rodig SJ; Chen BJ; Woda BA; Yu H
    Am J Surg Pathol; 2014 Jun; 38(6):776-83. PubMed ID: 24705315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
    Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
    Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review.
    Kaur J; Valisekka SS; Hameed M; Bandi PS; Varma S; Onwughalu CJ; Ibrahim H; Mongia H
    Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):e195-e212. PubMed ID: 36966041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Biomarkers in the Progression From MGUS to Multiple Myeloma: A Systematic Review.
    Cosemans C; Oben B; Arijs I; Daniëls A; Declercq J; Vanhees K; Froyen G; Maes B; Mebis J; Rummens JL
    Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):235-248. PubMed ID: 29506935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
    Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
    JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma cell neoplasms and related entities-evolution in diagnosis and classification.
    Fend F; Dogan A; Cook JR
    Virchows Arch; 2023 Jan; 482(1):163-177. PubMed ID: 36414803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of short-term, progressive exercise training on disease activity in smouldering multiple myeloma and monoclonal gammopathy of undetermined significance: a single-arm pilot study.
    Emery A; Moore S; Crowe J; Murray J; Peacock O; Thompson D; Betts F; Rapps S; Ross L; Rothschild-Rodriguez D; Arana Echarri A; Davies R; Lewis R; Augustine DX; Whiteway A; Afzal Z; Heaney J; Drayson MT; Turner JE; Campbell JP
    BMC Cancer; 2024 Feb; 24(1):174. PubMed ID: 38317104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study.
    Campbell JP; Heaney JLJ; Pandya S; Afzal Z; Kaiser M; Owen R; Child JA; Cairns DA; Gregory W; Morgan GJ; Jackson GH; Bunce CM; Drayson MT
    Lancet Haematol; 2017 Dec; 4(12):e584-e594. PubMed ID: 29146225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.
    Mailankody S; Mena E; Yuan CM; Balakumaran A; Kuehl WM; Landgren O
    Leuk Lymphoma; 2010 Dec; 51(12):2159-70. PubMed ID: 20958231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.
    Burgos L; Tamariz-Amador LE; Puig N; Cedena MT; Guerrero C; Jelínek T; Johnson S; Milani P; Cordon L; Perez JJ; Lasa M; Termini R; Oriol A; Hernandez MT; Palomera L; Martinez-Martinez R; de la Rubia J; de Arriba F; Rios R; Gonzalez ME; Gironella M; Cabañas V; Casanova M; Krsnik I; Perez-Montaña A; González-Calle V; Rodriguez-Otero P; Maisnar V; Hajek R; Van Rhee F; Jimenez-Zepeda V; Palladini G; Merlini G; Orfao A; de la Cruz J; Martinez-Lopez J; Lahuerta JJ; Rosiñol L; Blade J; Mateos MV; San-Miguel JF; Paiva B;
    J Clin Oncol; 2023 Jun; 41(16):3019-3031. PubMed ID: 36930848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression of monoclonal gammopathy of undetermined significance to multiple myeloma is associated with enhanced translational quality control and overall loss of surface antigens.
    Ravn Berg S; Dikic A; Sharma A; Hagen L; Vågbø CB; Zatula A; Misund K; Waage A; Slupphaug G
    J Transl Med; 2024 Jun; 22(1):548. PubMed ID: 38849800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.
    Zingone A; Kuehl WM
    Semin Hematol; 2011 Jan; 48(1):4-12. PubMed ID: 21232653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.